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45
46 Abstract:
47
48 The human gastrointestinal tract is home to the most diverse microbial ecosystem in the human body and is made up of bacteria, 
49 viruses and eukarya. Collectively known as the gut microbiota, our knowledge of these microbial communities has historically been 
50 restricted by the relative limitations of culturing techniques. However, the recent development and utilisation of next-generation 
51 sequencing techniques has enhanced our understanding of its structure, diversity and function.
52
53 There is emerging evidence that the gut microbiota plays a pivotal role in both health and disease. Perturbations to the structure and 
54 function of the gut microbiota are known to be associated with certain disease states. Therefore, manipulating the gut microbiota in 
55 an attempt to restore structure and function represents a promising therapeutic strategy. Recently, there has been a surge in clinical 
56 and scientific interest in manipulating the gut microbiota using a method called faecal microbiota transplantation. This increase in 
57 interest has gathered after it was shown in randomised controlled trials to be highly effective in treating recurrent Clostridium difficile 
58 infection. 
59
60 Despite success in treating recurrent Clostridium difficile, there remain many unknowns about how best to optimise its preparation, 
61 regulation, mode of delivery and safety. This review aims to summarise the literature surrounding the current knowledge regarding 
62 faecal microbiota transplantation and explore potential future research avenues that aim to enhance the safety, efficacy and utilisation 
63 of faecal microbiota transplantation.
64
65
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66 1 Introduction
67
68 The human gastrointestinal tract is home the most dense, rich and diverse microbial ecosystem in the human body. The highest 
69 concentration of microbes live within the colon, where there are an estimated 1012 cells per gram of intestine luminal contents (1). 
70 These microbial communities, the habitat they live in, and their spectrum of activity are collectively known as the gut microbiome. In 
71 this review, the term ‘microbiota’ will be used when reference is made to only the microorganisms themselves and the term 
72 ‘microbiome’ will be used when referring to the microbial communities, their genetic potential and the environment that they occupy.  
73
74 The gut microbiome is composed of archaea, bacteria, viruses and eukarya (2). The vast majority of research into the gut microbiome 
75 that has been conducted to date has focussed on the structure and function of the bacterial communities. By contrast, there has been 
76 relatively sparse research conducted on the viruses and bacteriophages (virome) (3), fungi (mycome) (4,5) and other micro-
77 eukaryotes such as protozoa (6). For the purposes of this review, the term ‘gut microbiota’ will refer to the bacterial communities that 
78 reside inside the intestinal tract, unless stated otherwise. 
79
80 Until relatively recently, the majority of knowledge relating to the gut microbiota has been acquired through culture-based techniques, 
81 which are labour-intensive and not high-throughput. Furthermore, they require specific conditions to optimise bacterial growth (e.g. 
82 an anaerobic environment) which inevitably means that much of the gut microbiota is missed. The invention and subsequent 
83 implementation of next-generation sequencing technologies have provided researchers with the apparatus and capabilities to analyse 
84 the gut microbiota without the need to culture microbes (7). Several international studies and initiatives, including large-scale 
85 endeavours such as the Human Microbiome Project and MetaHit, have used these tools to identify over 1000 species within the gut, 
86 mainly belonging to four major phyla, namely: Actinobacteria, Proteobacteria, Firmicutes, and Bacteroides (2)(8). These large cohort 
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87 studies also showed that relative abundance of these phyla differs between individuals (9). However, the clinical and biological 
88 significance of these observations is currently poorly understood.
89
90 Microbial sequencing enables us to know which microbiota community members are present but are unable to elicit their specific 
91 role. In view of this, numerous experiments have been undertaken to better understand the function of the gut microbiota (10,11). 
92 These experiments have shown that the bacterial communities underpin several important physiological functions such as nutrient 
93 absorption, bile and short chain fatty acid metabolism, activity of the immune system, vitamin production and protection from 
94 xenobionts (12). The functions of the gut microbiota appear to be ubiquitous across the healthy population (9). In contrast, the 
95 structure and composition of the gut microbiota appears to differ between people. The significance of differences in structure and 
96 composition of the microbiota between person to person is currently unclear. However, is it known that a sensitive and complicated 
97 symbiosis exists between humans and their microbial inhabitants. Disturbances to this symbiotic relationship is known to have 
98 deleterious effects on the host. For example, in the case of Clostridioides (formerly Clostridium) difficile infection (CDI), the use of 
99 broad-spectrum anti-microbial agents disrupts normal microbial diversity and function. This in turn, allows germination, colonisation 
100 and toxin production by C. difficile, resulting in clinical symptoms of diarrhoea often associated with blood, pain and significant 
101 morbidity and mortality if left untreated. Therapeutic modalities focussed on restoring gut microbiota diversity and function are 
102 emerging and represent a promising therapeutic strategy. For example, a medical treatment called Faecal Microbiota Transplantation 
103 (FMT), has shown efficacy in randomised controlled trials for treatment of recurrent CDI (13).
104
105 This review provides an update on current understanding of FMT for CDI and gives an insight into best practice for all aspects of the 
106 treatment. The evidence for FMT in indications beyond CDI is also discussed.  
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107
108 2 Clostridioides difficile infection (CDI) 
109
110 Clostridioides difficile, is an anaerobic, spore-forming, toxin producing bacterium that colonises the intestinal tract of around 2-5% of 
111 the healthy population (14). It was first isolated by Hall & O’Toole in 1935 from the gut of a healthy newborn baby  (15). However, its 
112 implication as a human pathogen was not known until 1978, when George and colleagues discovered that Clostridioides difficile was 
113 heavily implicated in many cases of antibiotic-associated diarrhoea. These days, it is known as the causative pathobiont in most 
114 cases of post-antibiotic infectious diarrhoea (12). In 2011, there were approximately 500,00 cases of CDI, resulting in 29,000 deaths 
115 in the USA (16). The European Centre for Disease Prevention and Control estimated using a point-prevalence survey that ~124,000 
116 patients developed health-care-associated CDI within the European Union annually. 
117
118 A detailed description of the pathogenesis of CDI is beyond the scope of this review. The major risk factor for the development of 
119 CDI is the use of broad-spectrum antimicrobial agents (17), which has led many to hypothesise that in health, the indigenous gut 
120 microbiota functions to prevent the germination and overgrowth of C. difficile (as well as other enteropathogens), a concept known 
121 as ‘colonisation resistance’. Potential mechanisms driving this phenomenon include the production of bacteriocins and phage by 
122 the indigenous communities, and alterations of gut microbiota-host metabolism interactions - which may impact competition for 
123 nutrients and physical space (18,19). As one example of interest, restoration of gut microbiota-mediated bile acid metabolism has 
124 been demonstrated after successful FMT for rCDI(20).  Particular bile acids have been demonstrated in vitro to have profound 
125 effects on different parts of the C. difficile life cycle, with the primary bile acid taurocholic acid being a major progerminant, and 
126 secondary bile acids (e.g. deoxycholic acid) inhibiting C. difficile‘s vegetative growth(21).  As such, the degradation of taurocholic 
127 acid and enrichment of gut secondary bile acids that accompanies FMT for rCDI(20) may be an important mechanistic explanation 
128 for FMT’s success.  
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130 There are a broad range of clinical manifestations of CDI, ranging from mild diarrhoea to life-threatening toxic megacolon (22). First 
131 line treatment for CDI involves stopping the inciting antibiotic and rehydrating the patient. Following this, the recommended treatment 
132 is a course of antibiotics. Those currently licensed in the EU are: metronidazole, vancomycin and fidaxomicin. Initial treatment is 
133 generally successful (23), however, the risk of recurrence within eight weeks is 15-25%, which rises to 40-65% in patients that have 
134 had more than a single recurrence (24). In patients with multiple relapses, the treatment options include: a pulsed/ tapered course of 
135 vancomycin or fidaxomicin, a novel anti-toxin B monoclonal antibody called Bezlotuzumab (25,26), and faecal microbiota 
136 transplantation (FMT). Despite these treatment options, there has been the emergence of hypertoxigenic strains of CDI, including 
137 027, which are less responsive to antimicrobial treatments and therefore drive the need for alternative treatment options (27).
138
139 3 Faecal microbiota transplantation (FMT): history and definitions  
140
141 In the late 1950’s, the Chief of Surgery at Denver General Hospital, Mr Ben Eiseman, decided that he would try to treat four of his 
142 patients suffering from post-antibiotic diarrhoea by transferring stool from a healthy donor into their intestinal tracts with good results. 
143 Since the pioneering work of Eiseman, a large body of controlled and non-controlled evidence has accumulated showing that FMT is 
144 a highly effective therapeutic strategy in patients suffering from recurrent CDI (28). A detailed analysis of the literature is presented 
145 in further detail in a later section of this review. 
146
147 A recent systematic review published by Quraishi and colleagues reported that across seven randomised trials and 30 case series, 
148 FMT was more effective than vancomycin in resolving recurrent and refractory CDI, with clinical resolution across all studies being 
149 95% (28). In contrast, the efficacy of vancomycin in patients with recurrent CDI not responsive to multiple courses of antibiotics is 
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150 known to be around 30% (24). In addition to recurrent and refractory CDI, a recent study reported that FMT also improves survival in 
151 patients suffering from severe CDI(29). 
152
153 The majority of FMT reported in the literature is allogenic in nature (Figure 1) and involves the transfer of faecal microbiota from a 
154 healthy donor into the intestinal tract of a recipient. However, it should be noted that FMT can also be autologous in nature (Figure 
155 2), where faecal microbiota is banked by a person and reinstated at a later date, potentially after medical treatment that alters the 
156 structure and/or function of the gut microbiome. A variety of methods can be utilised to deliver the faecal microbiota as part of the 
157 procedure, such as nasoduodonal tube, nasogastric tube, rectal enema and the biopsy channel of a colonoscope (14). Recently, 
158 there has been interest in delivering the faecal microbiota through enteric coated capsules (30,31). Enteric coated capsules aid the 
159 design of placebo controlled studies and remove the need for the invasive medical procedures currently used to administer the faecal 
160 microbiota. However, in the studies, patients were asked to swallow 30-40 capsules, which could potentially pose problems for certain 
161 groups of patients in particular, e.g. with swallowing disorders. In light of this, the optimal delivery method remains unclear and future 
162 research should determine if the capsule burden can be decreased (32). 
163
164
165
166
167
168
169
170
171
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172 Figure 1: A schematic overview of allogenic and autologous Faecal Microbiota Transplantation using banked frozen faecal 
173 microbiota.
174
175
176
177 4 Current regulatory landscape
178
179 There is worldwide variation in the regulation of faecal microbiota for therapeutic application (33). In some countries, such as the UK 
180 (34), the USA (35) and France (36), faecal microbiota is regulated as a medicinal product. In others, such as Italy, it is regulated as 
181 a tissue and in others, such as the Netherlands, there are currently no regulatory guidelines (37). In the USA, despite announcing 
182 that faecal microbiota is regulated as a medicinal product, the FDA has opted to exercise enforcement discretion for FMT used for 
183 recurrent or fulminant CDI which fail to respond to standard therapy (38). In Europe, the EU commission provided a legal opinion on 
184 the regulation of FMT in December 2014. The commission considered that for the purposes of the EU Tissues and Cells Directive 
185 (EUTCD), faecal microbiota is a ‘combined substance’, meaning that it contain human cells and other components not from human 
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186 origin. There is a precedence for combined substances falling under the EUTCD. However, the commission concluded that for the 
187 purposes of FMT, the cells are not the active component of this substance and therefore are not ‘intended for human applications’ 
188 within the definition of the EUTC. In the future, it is possible that these policies and stances will evolve in time as the evidence base 
189 for FMT matures and progresses. 
190 5 FMT practicalities in clinical practice 
191
192 5.1 Donor screening and selection 
193
194 Historically, patients were encouraged to select their own donor from friends and family. However, evidence has emerged showing 
195 that faecal microbiota obtained from unrelated ‘universal donors’ is equally efficacious (30). Furthermore, there is evidence from blood 
196 transfusion medicine showing that recipient-selected donors are not less likely to test positive for infectious disease than unrelated 
197 ‘universal’ volunteer donors(39). These data, coupled with evidence showing that faecal microbiota can be frozen with a 
198 cryoprotectant and banked for over six months at -80 degrees Celsius (40) without a loss of viability and efficacy (13) has prompted 
199 many centres to set up donor programmes using pre-screened unrelated donors who are anonymous to the recipient. Frozen banking 
200 also allows for stool to be quarantined, which has the added benefit of reducing the risk of infectious pathogens not being picked up 
201 because of screening being performed during a seroconversion window. The concept of frozen banking is well established, however, 
202 the duration of quarantine and the frequency of retesting is less well agreed. 
203
204 Currently, there is no consistent evidence that links donor characteristics to any influence on patient outcomes. In light of this, donor 
205 screening is focussed on risk reduction (41). Consensus guidance published by Cammarota et al (32) recommends that donors are 
206 extensively screened by a medical questionnaire prior to undergoing blood and stool testing. The medical questionnaire is usually 
207 designed to elicit information regarding risk factors for transmittable pathogens and conditions and diseases that could potentially be 
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208 microbiome-mediated (32). As a general rule, prospective donors with active infection or who disclose risk factors for infection should 
209 be excluded. Regarding microbiome-mediated conditions and diseases, as FMT involves the transfer of a largely uncharacterised 
210 active microbial suspension, there is a theoretical possibility that a propensity to diseases linked to the gut dwelling microbial 
211 communities could be transferred (6). Therefore, it is recommended that centres and doctors adopt microbiome-specific exclusion 
212 criteria, such as diagnosed metabolic disorders and obesity, a personal or family history of gastrointestinal disease and a family 
213 history of colorectal cancer (42). 
214
215 There is relative uniformity different centres and countries (Table 1) with regards to blood screening protocols.  By analogy, it may be 
216 best practice to try and match the serostatus of donors to patients for CMV and EBV which is likely to be an important consideration 
217 in immunocompromised recipients. 
218
219 Table 1: A table outlining blood testing protocols in a number of commercial and non-commercial stool banks. These are presented 
220 alongside EU consensus guidance published by Cammarota et al (32). 
OpenBiome(43) NDFB(37) EnteroBiotix EU 
Guidance(32)
Test
CMV - X  X X
EBV - X  X X
Hepatitis A X X  X X
Hepatitis B X X  X X
Hepatitis C X X  X X
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Hepatitis E X X  X X
HIV Type 1/2 X X  X X
HTLV X X  X X
Treponema X X  X X
Strongyloides X X  X X
221
222 In contrast to the general uniformity and convergence observed in Table 1 between donor blood testing protocols, stool screening 
223 protocols vary between centres and countries (37). In general, clinical trials appear to adopt similar testing protocols to those outlined 
224 in the seminal randomised controlled trial published by Van Nood et al (13,44,45). Between stool banks, most of the variation between 
225 protocols is found between policies on screening for multi-drug resistant organisms, as well as contagious viruses such as Astrovirus 
226 and Sapiovirus (37). In the absence of robust data on optimal donor testing and management, centres should take a multi-disciplinary 
227 approach to developing screening protocols and processes. The current consensus guidance criteria for screening and subsequent 
228 selection will likely be updated to reflect improved understanding of transferring potential pathogens through FMT.
229
230 5.2 Recipients of FMT
231
232 FMT works for recurrent CDI, and probably also refractory CDI, although refractory is a term that is poorly-defined. Interestingly, 
233 recent data suggests that FMT may be a suitable alternative to antibiotic treatment in primary CDI (46) although numbers in the 
234 studies are small to make definitive conclusions and recommendations. There are many unknowns about who should and shouldn’t 
235 receive FMT. Many studies involving FMT have excluded patients who are immunocompromised, pregnant, (47,48)  as well as those 
236 with chronic diarrhoea(47–49), decompensated cirrhosis (48) and those with food allergies (48,50). Whilst there is little evidence that 
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237 these exclusions are associated with significant risk from FMT, it should be offered with caution in these patient groups and based 
238 on theoretical risk avoided in those patients with anaphylactic food allergies.
239
240
241 5.3 Faecal processing and storage 
242
243 The methods, techniques and processes for faecal collection and preparation prior to administration have not been standardised and 
244 vary across the literature. Guiding principles have, however, been published in consensus papers.(32,51) Faecal material should be 
245 collected from donors in a designated clean air tight collection container. Once the stool has been obtained, it is advisable to process 
246 the sample within six hours (49) to preserve as much viability as is practically possible. European consensus guidance recommends 
247 that >30g of faecal microbiota is used per FMT. However, we recommend that this is increased to >50g of in light of evidence showing 
248 that that using <50g increases the risk of CDI recurrence (52). Once weighed out, stool is usually homogenised with an excipient so 
249 that it can be infused as part of the FMT procedure. The most commonly used in the literature is physiological saline, however, other 
250 excipients such as water (53) and milk (54) have been described previously. After homogenisation, the faecal microbiota is usually 
251 filtered to remove large particulates. If the material is to be frozen, then glycerol or another cryoprotectant should be added to the 
252 suspension to preserve the viability of the bacterial communities when the suspension is frozen. There is data showing that faecal 
253 microbiota remains viable and efficacious for six months when frozen with glycerol (45). 
254
255 5.4 FMT preparation and procedure
256
257 On the day of the procedure, frozen faecal microbiota preparations should be thawed overnight in a refrigerator or at room temperature 
258 (55) for several hours. The Netherlands Donor Faeces Bank recommends 5 hours of thawing if at room temperature (37). Thawing 
259 the preparation in a water bath is not recommended as there are published reports of water baths causing microbial entry during the 
260 thawing process in blood transfusion medicine (56). 
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261
262 Patients undergoing FMT are typically asked to discontinue antibiotic therapy 1-3 days before the procedure. European consensus 
263 guidance also recommends the use of bowel lavage the day before FMT. It has been suggested that this may reduce the abundance 
264 of C. difficile and potentially remove any residual antimicrobial in the colon, and enhance engraftment of the donor faecal microbiota 
265 (51) however these hypotheses have yet to be tested in a robust randomised controlled clinical trial. 
266
267 Further patient preparation to be considered is the use of proton pump inhibitors (PPI) prior to upper GI FMT. This theoretically helps 
268 to minimise acidity which may impair engraftment of transplanted microorganisms. Importantly, whilst some studies advocate the use 
269 of PPI prior to receiving FMT via the upper GI route (57–63), there appears to be no difference in efficacy when PPI has not been 
270 utilised. The use of a prokinetic for FMT via upper GI route has been described (64) and theoretically can reduce the risk of aspiration 
271 when utilising this route. When considering lower GI administration loperamide and other anti-motility medications have been utilised 
272 with the aims of prolonging FMT exposure to the gut and aid retention of the FMT(65–67). Whilst these additional patient preparation 
273 points should be considered, there is limited evidence for their use. 
274
275 As briefly outlined earlier in this review, there are several potential routes of administration for FMT. These are: (a) instillation of faecal 
276 microbiota into the upper GI tract through nasogastric or nasoduodenal tube (13), (b) instillation into the colon by colonoscopy (44) 
277 or flexible sigmoidoscopy(c) instillation into the colon/rectum through an enema(53) and finally (d) administration through orally-
278 delivered capsules (30). The optimal route of delivery remains unclear, with each having potential benefits and drawbacks. For 
279 example, upper GI administration may require less sedation than colonoscopy but several studies have shown that colonic delivery 
280 may provide a slight, but not statistically significant, efficacy benefit (28,58,68). In addition, there have been several documented 
281 cases of aspiration pneumonia (59,69) as a result of upper GI delivery (see Section 7). Further RCT’s are required in order to 
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282 establish the optimal route of administration. Clinicians seeking to administer FMT should approach each clinical situation where FMT 
283 is potentially indicated on a case by case basis, taking the patients comorbidities and preferences into account. 
284 6 Fresh Vs Frozen
285
286 Two randomised studies have evaluated the efficacy of fresh FMT versus frozen FMT. In one non-inferiority study, it was found that 
287 that a frozen enema of FMT (n=91) was non-inferior for clinical resolution of diarrhoea to fresh FMT (n=87) for the treatment of 
288 recurrent or refractory CDI(55). The other study supported this finding, and suggested that remission rates for CDI were similar when 
289 comparing fresh and frozen FMT delivered via colonoscopy (n=25/25 vs 20/24 respectively, p=0.233(65)). 
290
291 On a logistical level, frozen FMT is likely to be the preferred choice due to ease of transferring from centralised stool banks, 
292 traceability, and from a regulatory perspective. Research has shown that stool banking is more cost effective than using directed 
293 donors and fresh samples(70). Furthermore, research has demonstrated that frozen stool retains its viability and efficacy for six 
294 months when stored in a -80oC freezer,(45,50,70) however decreasing viability of the gut microbiota has been shown beyond this 
295 period.
296 7 Adverse events and unintended consequences
297
298 Those adverse events reportedly occurring around the time of administration of the faecal microbiota FMT tend to be related to the 
299 procedure itself.  Procedural adverse events described after colonoscopic administration include mild nausea and vomiting (attributed 
300 to sedation for the colonoscopy), and minor mucosal tears during colonoscopy. A case of microperforation (71,72) following biopsy 
301 of an area of possible small bowel ischaemia in a patient with chronically dilated small bowel has also been reported; the case was 
302 subsequently successfully treated conservatively(66). One death due to witnessed aspiration at the time of colonoscopy has been 
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303 described (73). Two deaths related to aspiration pneumonitis that are likely attributable to upper GI administration of FMT have been 
304 reported (73,74) along with several cases of regurgitation and vomiting (74). However, some of these patients were receiving a 
305 considerably higher volume of FMT than is typically administered by the upper GI route (i.e. 500ml) (74). One of the fatal episodes 
306 using higher volumes occurred in a patient with a swallowing disorder following oropharyngeal radiation after surgical removal of a 
307 maxillary carcinoma. Many centres using smaller volumes of FMT for upper GI administration have not consistently noticed similar 
308 problems.  
309
310 In the hours to days following FMT, the most common adverse events are constitutional or gastrointestinal symptoms, including 
311 diarrhoea, abdominal cramps/pain, belching, constipation and nausea (74). These are typically mild and self-limiting.  Successful 
312 treatment usually centres around conservative management. However, it should be noted that a recent meta-analysis described a 
313 22.7% rate of worsening of IBD activity in patients with IBD that received FMT as treatment for rCDI (75) but the authors of this study 
314 did note significant heterogeneity in the reviewed literature.  Further studies are required to further delineate the relationship between 
315 FMT and risk of IBD flare.  
316
317 There are concerns about the risk of transmission of infection from donor to recipient through FMT. However, there are very few 
318 reports of this in the literature. Two cases of Norovirus infection occurring soon after FMT have been reported, however, the authors 
319 concluded that these infections were more likely to represent environmental transmission rather than direct donor-to-recipient transfer 
320 (76). 
321
322 Beyond what has been described above, there have been reported cases of autoimmune and inflammatory conditions developing 
323 soon after FMT. These include: microscopic colitis, Sjögren’s syndrome, follicular lymphoma, peripheral neuropathy, immune 
324 thrombocytopenia and rheumatoid arthritis (77,78). It should be noted, however, that these observations have only been published 
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325 in case reports and have not been replicated in randomised controlled trials.  A widely-publicised case study reported marked weight 
326 gain in a patient being treated for recurrent CDI using an overweight family member as a donor(79). These results have not been 
327 replicated elsewhere in the literature and therefore does not seem likely to be a true risk (80).    
328
329 As faecal microbiota contains a largely uncharacterised consortia of microorganisms, there is a theoretical risk that FMT could transfer 
330 a disease phenotype from the donor to the recipient. Long-term, prospective follow-up of recipients is required to fully assess this risk 
331 and donor screening programmes should be designed to exclude donors that are most likely to harbour significant risk. 
332 8 Efficacy in Non-CDI indications
333
334 The role of FMT has been explored in a multitude of indications beyond CDI. Most of the research that has been conducted has been 
335 uncontrolled and there is significant heterogeneity between case reports and case series that report positive outcomes (81). There is 
336 likely to be a significant degree of reporting bias and therefore the positive outcomes should be approached with caution. However, 
337 there have been studies published in several indications beyond CDI, including: ulcerative colitis, metabolic syndrome, functional 
338 bowel disorders, hepatic encephalopathy and multi-drug resistant organisms.  
339
340 8.1 Ulcerative colitis
341
342 To date, there have been four RCTs (three published, one abstract) investigating clinical endpoints in UC following treatment with 
343 FMT (44). Three of these four RCTs showed positive outcomes, with patients receiving donor FMT more likely to reach clinical 
344 endpoints of response and remission compared to placebo or autologous FMT. However, these studies differed in methodology, with 
345 variations in patient inclusion criteria, donor stool processing and preparation, administration and the faecal microbiota infusions. The 
346 successful studies delivered the faecal microbiota through the lower GI route and used a more intense treatment protocol with up to 
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347 a total of 40 over 8 weeks. Interestingly, the RCT that prepared the faecal microbiota under anaerobic conditions resulted in the 
348 highest clinical response and remission. 
349
350 8.2 Functional bowel disorders
351
352 There have been two RCTs that have been published investigating the use of FMT as a treatment for functional bowel disorders. 
353 These two studies report positive outcomes. A Norwegian study of 90 patients with diarrhoea-predominant irritable bowel syndrome 
354 (IBS) demonstrated that a an improvement in IBS severity scores in those who received a single infusion of FMT compared to those 
355 who received placebo(82). A second study showed marked improvement in spontaneous bowel movements in 60 patients with slow 
356 transit constipation receiving six infusions of FMT when compared to conventional treatment (83). 
357
358
359 8.3 Metabolic syndrome
360
361 To date, there have been two studies investigating the efficacy of FMT in patients with metabolic syndrome(84). Both of these studies 
362 suggested that FMT from lean donors may improve peripheral insulin sensitivity in patients suffering from metabolic syndrome. In 
363 both studies the effect size was deemed to be statistically significant. However, the effects were transient (with benefits found only at 
364 six weeks – but no longer – post-FMT), which suggests that long-term repeated dosing may be required if FMT is to potentially be an 
365 effective treatment option in metabolic syndrome. 
366
367 8.4 Hepatic encephalopathy
368
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369 In a study of 20 patients suffering from hepatic encephalopathy caused by liver cirrhosis, improvements in encephalopathy and a 
370 reduction in cirrhotic complications were noted in the FMT arm, but not amongst patients receiving standard of care medical 
371 therapy(85).  However, as the patients in the FMT arm in this study also received antibiotics (rifaximin) and lactulose throughout, the 
372 results should be interpreted with caution. 
373
374 8.5 Decolonisation of multidrug resistant organisms
375
376 There is a growing interest that FMT may promote decolonisation of multidrug resistant organisms(86–88). As yet there are no 
377 randomised controlled studies that explore this but it is gathering interest and may provide a novel therapeutic avenue to target 
378 multidrug resistant organisms.
379 9 Conclusion and future perspectives 
380
381 FMT is an effective treatment for recurrent CDI regardless of the route of delivery and method of preparation and storage. The use 
382 of encapsulated and orally administered faecal microbiota will expand access for patients and simply the design of placebo controlled 
383 trials.  Short-term follow-up suggests that FMT appears to be a relatively safe treatment, with the majority of side effects being mild 
384 and self-limiting. The long-term sequelae of FMT are currently not known and future work should focus on investigating this. There is 
385 emerging evidence suggesting that FMT may have a treatment utility beyond recurrent CDI, although further RCT evidence is required 
386 before wide scale adoption may occur for these indications. In the future, it is possible that FMT may ultimately be replaced by defined 
387 consortia of bacteria or single strains that have been rationally-selected based on their mechanism of action. There are several 
388 commercial and non-commercial organisations and groups working on this (89). However, it should be noted that faecal microbiota 
389 is a highly complicated starting substance and those that wish to reverse engineer it will probably have to elucidate the ways in which 
390 the microbial communities within the samples interact with each other, as well as unravelling its mechanism of action. In light of this, 
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391 it may be quite some time before an optimal combination of microbes is discovered and ultimately taken into the clinic. Until then, 
392 doctors and researchers should focus on making FMT as safe and effective as possible by adhering to consensus guidance 
393 recommendations and supporting interventional FMT studies. 
394
395
396
397
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400
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402
403
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406
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409
410
411
412
413
414
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437 Table 1. A table outlining published Randomised trials of FMT in in C.diff infection
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Demographics
 
Author FMT vs 
comparison
N M/F Age
Donors Route Fresh/frozen (dose)
comparator
Outcome 
FMT arm 7 4/3 Mean 
of 
46.7 
(+/- 
15.8) 
years.
>18years, 
non-
pregnant, 
BMI 20-
25kg/m2
Upper 14
Lower 1
Frozen 45ml of pooled 
donor stool (from three 
donors), at ~0.19g/ml
71.4% (n=5/7) Camacho-Ortiz et 
al, PLoS ONE, 
2017
Vancomycin 9 6/3 Mean 
of 
46.7 
(+/- 
15.8) 
years.
n/a oral 250 mg every 6 hours 
for 10-14 days
 88.9% (n=8/9
FMT 20 8/12 Mean 
71 
(range 
29-89) 
years.
Less than 
50 years of 
age, no 
antibiotics 
within past 6 
months
All lower Fresh- dose not 
specified
90% (n=18/20).Cammarota et al,
Alimentary 
Pharmacology and 
Therapeutics,
2015
Vancomycin ( 19 8/11 Mean 
75 
(range 
n/a Oral 125mg four times daily 
for 10 days, follow by a 
pulse regimen (125-
26% (n=5/19).  
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49-93) 
years.
500mg/day every 2-3 
days, for at least three 
weeks).  
FMT capsules 
(30 pills once).
10 Not 
stated
Not 
stated
Donors were 
unrelated 
donors from 
universal 
stool bank 
(OpenBiome
Oral Frozen-30 pills once 70% (n=7/10).Allegretti et al,
Gastroenterology 
(abstract),
2016
FMT capsules 
30 pills daily on 
two consecutive 
days
9 Not 
stated
Not 
stated
Donors were 
unrelated 
donors from 
universal 
stool bank 
(OpenBiome
oral Frozen-30 pills daily on 
two consecutive days
77.8% (n=7/9).
FMT 16 5/11 75.7 
+/- 
14.5 
years.
.
Not stated lower Fresh -50g 43.8% (n=7/16).Hota et al,
Clinical Infectious 
Diseases,
2016
Vancomycin 12 4/8 Mean 
69.6 
+/- 
14.2 
years
Not stated oral vancomycin 125 mg 
orally every 12 hours 
for 1 week; then, 
vancomycin 125 mg 
orally every 24 hours 
for 1 week; then, 
vancomycin 125 mg 
orally every second day 
for 1 week; then, 
vancomycin 125 mg 
orally every third day 
for
58.3% (n=7/12).
Jiang et al,
Alimentary 
Pharmacology and 
Therapeutics,
2017
FMT 25 4/21 Mean 
75 
(range 
19-97) 
years
Not stated Lower Fresh and frozen-50g Fresh 100% 
(n=25/25)
Frozen 83% 
(n=20/24).
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Lyophilised 
FMT.25
24 6/18 Mean 
62.5 
(range 
33-88) 
years.
Not stated Lower Frozen-50g 78% (n=20/23).
FMT capsules 57 14/43 Mean 
58.7 
(+/-
18.5) 
years.
Unrelated Oral Frozen-80-100g 96.2% (n=51/53)Kao et al, JAMA, 
2017
Colonoscopic 
FMT
59 13/36 Mean 
57.4 
(+/-
19.1) 
years.
Unrelated Colonoscopic Frozen-80-100g 96.2% (n=50/52).
Donor FMT 22 4/18 Mean 
age 
48 (+/-
16) 
years
Not stated Colonoscopic Fresh Mean stool dose 
of 64 g (standard 
deviation of 25 g; 
range, 20 to 100g).
90.9% (n=20/22).Kelly et al,
Annals of Internal 
Medicine,
2016
Autologous FMT 24 5/19 Mean 
age 
55 (+/-
14) 
years.
Not Stated Colonoscopic Fresh Mean stool dose 
of 64 g (standard 
deviation of 25 g; 
range, 20 to 100g).
62.5% (n=15/24).
Lee et al,
JAMA,
2016
Frozen FMT 108 36/72 Mean 
age 
73.0 
(+/- 
16.4) 
years.
Unrelated 
volunteers
Enema Frozen-100g 90.7% (n=98/109).
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Fresh FMT 111 37/74 Mean 
age 
72.5 
(+/- 
16.2) 
years.
Unrelated 
volunteers
Enema Fresh-100g 85.6% (n=95/111).
FMT 16 8/8 Mean 
73 (+/- 
13) 
years.
Healthy 
volunteers
Upper Fresh A mean (+/-
standard deviation) of 
141+/-71g of faeces 
was infused. 
94% (n=15/16)van Nood et al,
New England 
Journal of 
Medicine,
2013
Vancomycin 13 10/3 69 (+/-
16) 
years.
N/a Oral 500mg orally four times 
daily for 14 days
23% (n=3/13)
Colonoscopic 
FMT
10 4/6 Mean 
50.4 
(+/- 
28.8) 
years.
Healthy 
volunteers
Colonoscopic Frozen-90mls of 
thawed FMT (41g)
100% (n=10/10)Youngster et al,
Clinical infectious 
diseases,
2014
Nasogastric 
FMT
10 5/5 Mean 
58.6(+
/-19.6) 
years.
Healthy 
volunteers
Nasogastric Frozen-90mls of 
thawed FMT (41g)
80% (n=8/10)
439
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440
441
442
443 Table 2: A table outlining published case series of FMT in in C.diff infection. Publications that included over 10 patients were included 
444 in the table. 
DemographicsAuthor Study 
level N M/F Age
Donors Route Fresh/frozen 
(dose)
Outcome within given 
follow-up period 
Aas et al 
Clinical Infectious Diseases 
2003
Case 
series
18 5/13 73+/-9 
(range 
53-88)
15 were family 
members, 3 
clinical 
volunteers. 
All 
Nasoga
stric 
Fresh 30g 15/18 90 days.
Agrawal et al 
Journal of Clinical 
Gastroenterology 
2016
Case 
series
146 100/46 78.6
(range 
65-97)
Identified by 
the patient or 
if not available 
provided by 
the physician.
Upper 
GI 16
lower 
GI 130
Fresh 
60-100g  
121/146 (83%)
Mean follow up was 
12.3 months (range 1-
48 months).
Alrabaa et al 
Transplant Infectious 
Diseases 
2017
Case 
series
13 5/8 69 
(range 
59-74)
 Unrelated All 
Nasodu
odenal 
Fresh 
12.5g 
11/13 at eight weeks 
post-FMT
13/13 at 5 days
Follow up up to 8 
weeks described. 
Brandt et al 
American Journal of 
Gastroenterology 
2012
Case 
series
56 21/56 65+/-17 
(range 
22-87)
 45 spouses/ 
partners 21 
relatives 1 
All 
Colono
scopic
Fresh 
6 
tablespoons 
70/77 after one 
infusion 
Follow-up period up to 
3 years
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Chin et al 
Clinical Gastroenterology & 
Hepatology 
2016
Case 
series
35 19/16 43 (8 -
93)
5 via 
nasoga
stric
3 
colonos
copy
Frozen 41g 
of stool on 
average 
frozen. 
Not stated
Cohen et al 
Israel Medical Association 
Journal 
2016
Case 
series
22 13/9 71.5 
(range 
16-92)
13 unrelated, 
rest related.
Nasodu
odenal 
10
Colono
scopic 
10
Fresh and 
frozen 60g 
stool 
average (35-
75g)
16/22 at 2 months
16/22 (5/10 upper (out 
of 7 analysed), 11/12 
for lower GI (out of 11 
analysed))
Results reported at 
2/12, but followed up to 
6/12 (7 in the upper, 5 
in the lower followed 
up to 6 months).
Costello et al 
Alimentary Pharmacology 
and Therapeutics 
2015
Case 
series
20 N/A Median 
age 69
4 healthy 
volunteers.
Upper 
GI  1 
Lower 
GI  19 
Frozen not 
stated
17/20 (85%)
Minimum 3 months 
(but up to 14 months).
Dubberke et al 
Clinical Infectious Diseases 
2016
Prospe
ctive 
case 
series
34 11/23 Median 
66.8 
(range 
26.7-
89.6)
 4 unrelated 
donors.
All 
enema
Frozen 50g 27(87.1%) after 8 week
16(51.6%) of those 
that recieved a second 
infusion 11/14(78%) 
were considered a 
success
6 month follow up in 31 
patients on safety.
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Emanuelsson et al 
Scandanavian Journal of 
Infectious Diseases 
2014
Case 
series
23 9/14 Mean 
66 
years
Donors were 
spouses or 
close relative.
All 
lower 
GI  23 
Fresh
50g 
15/23 (65%)
Median follow up of 18 
months (range 0-201 
months).
Fischer et al 
Inflammatory Bowel 
Diseases 
2016
Case 
series
67 28/39 mean 
age 
45.42+/
- 17.33
Patient 
directed donor 
or unrelated 
healthy 
volunteer.
months
All 
lower 
GI  
Fresh did not 
specify
60 (90%) within 3 
months
53 (79%)
average length 10.4 
months (range 3-36).
Fischer et al 
American Journal of 
Gastroenterology 
2016
Case 
series
328 87/241 Mean 
age 
61.4
+/- 19.3
130 ( 40%) 
patient 
directed 
donors 198 
(60%) 
universal 
donors. 
Upper 
GI not 
specifie
d 
Lower 
GI  
249(76.
9%) 
Not specified 1 month 81.4%, 1-3 
months 97.3%
NS
Fischer et al 
Gut Microbes 
2017
Case 
series
57 23/34 72 (60-
7925-
99)
Patient 
selected donor 
in first 28. 
Donor 29 from 
OpenBiome 
stool bank.
All via 
colonos
copy or 
sigmoid
oscopy.
Fresh
Did not 
specify
91% (n=52/57), i.e. 
100% severe CDI 
(n=19/19), and 87% 
(n=33/38).
Fischer et al 
Alimentary Pharmacology 
and Therapeutics 
2015
Case 
series
 29 12/17 Mean 
overall 
of 65.2 
years+/
Either patient 
selected-
donor or 
universal 
All via 
flexible 
sigmoid
oscopy 
Fresh 50-
200g of stool
3/12 - 18/29 in 
remission
7/10 in severe arm 
9/19 in severe/ 
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-17.9 
(25-92 
years) 
mean 
60.8 
(26-87) 
in 
severe 
67.6 
(60-78) 
in 
severe/
complic
ated
donor 
screening in 
all cases. If 
patient-
directed, same 
donor used for 
subsequent 
FMTs if 
required. 44 
total FMTs 
administered - 
patient- 
selected donor 
for 16, 
universal 
donor for 28.
or 
colonos
copy 
complicated arm
Up to 3 months f/u.
Garborg et al 
Scandanavian Journal of 
Infectious Diseases 
2010
Case 
series
40 19/21 Median 
75 
(range 
53-94) 
years
Close 
relatives/ 
household 
members.
Upper 
GI 38
Colono
scopy 2
Fresh 50-
100g
33/40
29/ 40 (28 in 
duodenum, 1 in colon)
Up to 80 days.
Girotra et al 
Digestive Diseases and 
Sciences 
2016
Case 
series
29 23/6 80.1+/-
6.49 
years 
mean 
(13 
patients 
70-79, 
14 
patients 
80-89, 
Patient-
selected 
family or 
friend.
Enteros
copy 29
Fresh
450cc - 
270cc
29/29
Reported 25.37+/- 12.8 
months f/u (range 8-50 
months). 
  
30
2 
patients 
> 90 
years)
Hagel et al 
Deutsches Arzteblatt 
International 
2016
Case 
series
133 47/86 Median 
75
IQR 
59.5 - 
81.5
No donor 
details
4 OGD, 
40 
enteros
copy, 
19 
nasoent
eric 
tube 
55 
'endosc
opic' 
(no 
further 
details) 
capsule 
13
2 
combin
ation of 
jejunal 
and 
colonos
Fresh and 
frozen. No 
dose details
No diarrhoea 30 days 
101/120 no diarrhoea 
90 days 72/92.
Median follow up 141 
days (IQR 50-353 
days).
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copic 
FMT 
Hamilton et al 
American Journal of 
Gastroenterology 
2012
Case 
series
43 12/31 59+/-21  6 related, 2 
spouse,2friend
s rest 
unrelated 
ultimately 
30/33 were 
universal and 
3 were patient 
selected.
All 
colonos
copy
Frozen 50g 95% within 2 months 
follow-up
86%%
2 months follow FMT 
and 3 months in one 
patient.
Hefazi et al
Mayo Clinic Proceedings
2017
Case 
series
23 10/13 Median 
66 
years 
(range 
23-88).
Donors fresh 
stool from 
family/ friends 
in 10 patients, 
frozen stool 
from standard 
donors in 13 
patients.
All 
colonos
copy 
not stated if 
fresh or 
frozen. 
Approximatel
y 50g 
11/12 of 
haematological 
malignancy patients 
(other patient died), 
8/10 solid malignancy 
patients.
19/22 by primary 
outcome criteria
Hirsch et al 
BMC Infectious Diseases 
2015
Case 
series
19 6/13 61
range 
26-92 
 3 unrelated.
Working in 
healthcare  ns,
All 
capsule
s. 
Frozen 2.3g 13(68%) 90 days
primary outcome 90 
days secondary 6 
weeks after this.
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Ianiro et al 
Clinical Microbiology and 
Infection 
2017
Case 
series
64 25/39
mean 
74
36 unrelated 
and 28 from 
related.
n
All 
Lower 
GI  
Not reported 97% at 8 weeks
44/64 (69%)
8 weeks.
Kassam et al 
Archives of Internal 
Medicine 
2012
Case 
series
27 14/13
69.4 
years 
(mean)
 Two healthy 
volunteers.
All via 
retentio
n 
enema
 
not stated if 
fresh or 
frozen 150g 
22/27 (81%)
Mean follow-up at 
427.3 days after 
transplant. 
Kelly et al 
Journal of Clinical 
Gastroenterology 
2012
Case 
series
26 2/24 59 
years 
(mean)
25/26 family 
members 1 
friend.
Working in 
healthcare  
All via 
colonos
copy
Fresh 68 
tablespoon
24/26 (92.3%)
follow-up mean 10.7 
months ranged from 2-
30 months.
Kelly et al 
American Journal of 
Gastroenterology 
2014
Case 
series
80 38/42 Age 
(mean/
median
)  ((75 
adults 
,5 
children
) adults 
not 
mentioned.
 Not 
reporte
d
Not reported 89% within a minimum 
of 12 weeks
62(78%)
12 weeks post FMT.
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53 
years 
range 
(20-88)  
paediat
rics 
10.9 
(range 
6.5–16)
Khoruts et al 
Clinical Gastroenterology & 
Hepatology 
2016
Case 
series
272 83/189 Mean 
57.2+/-
19.2 
years 
median 
59.0 
(range 
16-100 
years)
As per 
Hamilton 
paper.
All via 
colonos
copy 
Frozen 50g 74% (n= 32/43) in IBD 
patients and 92.2% 
(n=211/229) in non-
IBD patients.
Lagier et al
European Journal of 
Clinical Microbiology and 
Infectious Diseases 
2015
Case 
series
61 21/40 Mean 
84 
years 
(66-
101)
Preferentially 
used healthy 
family 
members, also 
used healthy 
volunteer 
students and 
residents.
All 
nasoga
stric
Fresh >30g Global death rate of 
3/16 in early transplant 
arm (day 20, day 37, 
day 166), 2/3 treated 
by tardive transplant 
(day 28, day 54).  
None of these patients 
died with evidence of 
CDI.
1/3 treated by tardive 
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FMT dead at day 31 
1/16 treated by early 
FMT dead at day 31
Lee et al 
European Journal of 
Clinical Microbiology and 
Infectious Diseases 
2014
Case 
series
94 41/53 Mean 
71.8 
years, 
range 
24-95
 Volunteers - 
no further 
details.
.
All via 
retentio
n 
enema 
Not defined 81 in remission after 
FMT, 5 in remission 
after FMT-abx-FMT, 
8 non-responders
follow-up 6 months
MacConnachie et al 
QJM 
2009
Case 
series
15 1/14 81.5 
median 
(range 
68-95 
years)
healthy related 
volunteers
All via 
upper 
GI   18
Fresh 30g or 
2cm fresh
15/18 (84%) 
“resolution
84%
90 days
Mattila et al 
Gastroenterology
2012
Case 
series
70
Mal
e 
28 
28/42 Mean 
73 
(range 
22-90 
years)
61 close 
relatives/ other 
household 
members in 9 
cases, healthy 
volunteers.
All via  
colonos
copy
Fresh 20-
30ml 
94% (n=66/70) (100% 
(n=34/34) of those with 
non-027, 89% 
(n=32/36) with 027) 
within 12 weeks
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Meighani et al 
European Journal of 
Gastroenterology and 
Hepatology 
2016
Case 
series
201 76/125 66.6+/-
18.3 
years
 Not defined. Upper 
GI  
nasoga
stric (+5 
through 
PEG) 
(76)
Lower 
GI  45 
enema, 
75 
colon 
Not defined 176/201
Each patient for 90 
days.
Meighani et al 
Dig Dis 
Sci 2017
Case 
series
201 77/124 Mean 
68.79+/
-16.78 
years 
for 181 
non-
IBD 
patients
mean 
46.9+/-
19.97 
for the 
20 IBD 
patients
Typically 
family 
members, but 
small number 
of unrelated 
universal 
donors.  
Amongst IBD 
cohort - 6 
patients had 
family 
members as 
donor, 
universal 
donor in other 
14.
Upper 
GI  5 
NG 
(IBD 
patients 
only not 
describ
ed re 
non-
IBD 
patients
) (5)
Lower 
GI  13 
colonos
copy 
(IBD 
patients 
Not defined 158/181 in non-IBD, 
15/20 in IBD 
31/181 non-IBD 
relapse within 90 days 
25/180 beyond 90 
days, 
5/20 IBD relapse within 
90 days/ 
4/20 beyond 90 days.
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only not 
describ
ed re 
non-
IBD 
patients
) 2 
retentio
n 
enema 
(IBD 
patients 
only not 
describ
ed re 
non-
IBD 
patients
) (15)
Patel et al 
Mayo Clinic Proceedings  
2013
Case 
series
31 14/17 Mean 
61.26+/
19.34 
years
 
Healthy family/ 
contacts of 
recipients - 14 
spouses, 9 
children, 5 
siblings, 3 
parents, 1 
niece, 1 
friend..
All 
Colono
scopy 
Fresh 115g 
(range 18-
397g) 
21/23 said diarrhoea 
no longer present at 1 
year, 
6/6 reported 
maintained 
improvement or 
resolution
3 months
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Pathak et al 
Clinical & Experimental 
Gastroenterology 
2013
Case 
series
12 4/8 Mean 
71.9 
range 
37 - 90 
years
Preferably 
family/ first 
degree 
relatives 
family used in 
all cases here.
Nasodu
odenal 
tube 1
colonos
copy 11 
Fresh About 
6-8 
tablespoons 
f
91.7% (n=11/12). Total 
follow up period 2-26 
months.
Rohlke et al 
Journal of Clinical 
Gastroenterology 
2010
Case 
series
19 2/17 Mean 
49
4 family, 14 
partner, 1 
housemate
All 
given 
via 
colonos
copy
Fresh 
350mls
20/20(100%)
19/20(95)
6 months to 5 years
Rubin et al 
Anaerobe 
2013
Case 
series
75 26/49 63 
median 
(6-94 
range)
Healthy close 
household 
member of 
patient.
All 
upper 
GI
30g fresh 59/75 (79%)
Up to 60 days.
Satokari et al 
Alimentary Pharmacology 
and Therapeutics 
2015
Case 
series
49
 
15/34 Overall 
with 
fresh 
mean 
52(22-
15 fresh FMT 
with individual 
donor, 11 
fresh FMT 
with universal 
All 
colonos
copy 
Fresh and 
frozen 
Approx 30g 
Fresh 96% (n=25/26) 
frozen 96% (n=22/23).
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81 
range) 
years 
frozen 
61(20-
88 
range) 
years
donor, 23 
frozen FMT 
with universal 
donor.
Total follow up period 
12 weeks.
.
Yoon et al 
Journal of Clinical 
Gastroenterology 
2010
Case 
series
12 3/9  66 
years 
(range 
30 - 86 
years)
Spouses/ 
partners as 
8/12 one son, 
two daughters, 
one 
granddaughter
.
All 
lower 
GI
Fresh weight 
unclear. 
approx 250-
450cc of 
FMT 
administered 
in total. 
Fresh
12/12 (with f/u ranging 
from 3/52 to 8 years 
Youngster et al 
JAMA 
2014
Prospe
ctive 
case 
series
20
1 
11/9 Median 
age 
64.5 yrs
Unrelated 
adult 
volunteers
All 
capsule
s
Fresh 48g 18/20 (90%)
14/20 (70%)
8 weeks.
Youngster et al 
BMC Medicine 
2016
Case 
series
180 Not 
known
7–95 
years 
(media
n 64)
Healthy 
volunteer 
donor
All 
capsule
s
Fresh 41g 91% at 8 weeks 
147/190 (82%)%
8 weeks 
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Zainah et al 
Digestive Diseases and 
Sciences 
2014
Case 
series
14 5/9 73.4+/-
11.9 
years
Donor was 
family 
member, or 
unrelated if 
family 
members not 
available.  12 
FMT from 
related donor 
(7 spouse, 5 
children) rest 
unrelated.
Nasoga
stric 
adminis
tration 
in all 
but one 
who 
had 
colonos
copic 
delivery
Fresh 30-
50g 
11/ 14 by seven days
10/ 14
Up to 100 days.
445
446
447
448
449
450
451
452
453
454
455
456
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457 Table 3: A table outlining published randomised controlled trials of FMT in diseases beyond CDI. 
458
DemographicsAuthor Study 
type 
N M/F Age
Donors Route of 
FMT/amount of 
stool vs 
comparator
Fresh/froze
n (dose)
Outcome within given follow-
up period/ cure within one 
infusion (total follow-up period)
Moayyedi et 
al.
Gastroenter
ology
2015
RCT Intervention
38
Comparator
37
Intervention
18/20
Comparator
26/11
Intervention
42.2+/-15.0 
years.
Comparator
35.8 +/- 12.1 
years.
unrelated 
volunteers 
Intervention
FMT, all via 2 
retention 
enema.
Comparator – 
water enema 
given via 
enema
Fresh and 
frozen 8.3g 
FMT arm
Remission rates 24% (n=9/38)
Clinical response rates 40% 
(n=15/38) had reduction in full 
Mayo score of at least 3 
points.
Water enema arm
Remission rates 5% (n=2/37) 
(p=0.03)
Clincial response rates 24% 
(n=9/37) had reduction in full 
Mayo score of at least 3 points 
(p=0.16).
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Rossen et 
al.
Gastroenter
ology
2015
RCT Intervention
23
Comparator
25
Intervention
12/11
Comparator
11/41
Intervention
40 (33-56) 
years.
Comparator
41 (30 – 48) 
years.
Healthy 
partners, 
relatives, or 
volunteers.
Intervention
Donor FMT
All nasogastric
Comparator
Autologous 
FMT
All nasogastric
Not stated if 
fresh or 
frozen120g
Donor faeces arm
Remission rates 30% 
(n=7/23)
Clinical response rates 
47.8% (n=11/23) at 12 
weeks.
Autologous faeces arm
Remission rates 20% 
(n=5/25), (p=0.51).
Clinical response
Paramsothy 
et al.
Lancet
2017
RCT Intervention
41
Comparator
40
Intervention
22/119
Comparator 
25/15
Intervention
35.6 (27.8-
48.9) years.
Comparator
35.4 (27.7-
45.6) years.
3-7 unrelated 
donors.
Intervention
Donor FMT 
(pooled)
All lower GI 5 
enemas per 
week following 
colonosopic 
delivery -5 
days on, two 
days off for 8 
weeks (40 
enemas per 
patient) 
Comparator
Isotonic saline
Frozen 
37.5g 
Donor FMT arm
Remission rates 275 
(n=11/41).
Clincial response rates 54% 
(n=22/41).
Placebo arm
Remission rates 8% 
(n=3/40) (p=0.021).
Clincial response rates 23% 
(n=9/40)  (p=0.04).
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With added 
colourant and 
orourant and 
glycerol 
cyroprotectant
Costello et 
al.
Journal of 
Crohn's and 
Colitis 
(abstract)
2017
RCT Intervention
38
Control
35
Intervention
Not stated
Control
Not stated
Intervention
Not stated
Control 
Not stated
Healthy 
volunteers
Intervention
Donor FMT 
(pooled)
All lower GI 
FMT via 
colonoscopy 
on day 0, 
followed by 2 
enemas on 
day 7 (38) 
capsule nil
Comparator
Autologous 
FMT
Frozen 50g 
of stool for 
first FMT, 
25g of stool 
in 
subsequent 
enemas.
Donor FMT arm
Remission rates 32% 
(n=12/38) in steroid-free 
remission at week 8.
Clinical response rates 55% 
(n=21/38).
Autologous FMT arm
Remission rates 9%. 
(n=3/35) in steroid-free 
remission at week 8 
(p<0.01).
Clinical response rates 20% 
(n=7/35) (p<0.01).
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Johnsen et 
al
Lancet 
Gastroenter
ology and 
Hepatology
2017
RCT Intervention
55
Control
28
Intervention
I19/36
Control
9/19
Intervention
44 (33-54) 
years.
Control
45 (34-57) 
years
Two 
volunteers 
screened at 
start and at 7 
months post 
donation.
Intervention
Donor FMT
Comparator
Autologous 
FMT
All 
colonoscopy 
Frozen 50 to 
80g 
Donor FMT arm
Remission rates 66% 
(n=36/55)
Autologous FMT arm
Remission rates 43% 
(n=12/28) (p=0.49).
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